Treatment-resistant detrusor overactivity - Underlying pharmacology and potential mechanisms

International Journal of Clinical Practice

Volumn 60, Issue SUPPL. 151, 2006, Pages 8-16

  Andersson, Karl Eric ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Afferent nerves; Detrusor contraction; Urinary incontinence

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 5 METHYLURAPIDIL; ADRENERGIC RECEPTOR; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; ATROPINE; BOTULINUM TOXIN A; CARBACHOL; CONNEXIN 43; DOPAMINE RECEPTOR; GABAPENTIN; MESSENGER RNA; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE RECEPTOR; PURINE P2X1 RECEPTOR; PURINE RECEPTOR; RESINIFERATOXIN; SEROTONIN RECEPTOR; TAMSULOSIN; TOLTERODINE;

ADRENERGIC TRANSMISSION; BLADDER CONTRACTION; BLADDER DYSFUNCTION; BLADDER FUNCTION; BLADDER INNERVATION; BLADDER NECK STENOSIS; CELL COMMUNICATION; CENTRAL NERVOUS SYSTEM FUNCTION; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HORMONAL REGULATION; HUMAN; MICTURITION; MYOELECTRICITY; NEUROGENIC BLADDER; NEUROMODULATION; NONHUMAN; OVERACTIVE BLADDER; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM FUNCTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SENSORY NERVE; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; URINARY FREQUENCY; UROTHELIUM;

EID: 33751324838     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01184.x     Document Type: Review

References (101)

1. Andersson K-E, Appell R, Cardozo L et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 3rd International Consultation on Incontinence. France: Health Publication Ltd, Editions 21, 2005: 811-54.
2. Andersson KE. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477-94.
3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
4. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
5. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity ? J.Urol 2006; 175: 191-4.
6. Andersson KE. Bladder activation: Afferent mechanisms. Urology 2002; 59 (5 Suppl. 1): 43-50.
7. Apodaca G. The uroepithelium: Not just a passive barrier. Traffic 2004; 5: 117-28.
8. de Groat WC. The urothelium in overactive bladder: Passive bystander or active participant ? Urology 2004; 64 (6 Suppl. 1): 7-11.
9. Birder LA. Role of the urothelium in urinary bladder dysfunction following spinal cord injury. Prog Brain Res 2006; 152: 135-46.
10. Birder LA, Kanai AJ, de Groat WC et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci USA 2001; 98: 13396-401.
11. Birder LA, Nakamura Y, Kiss S et al. Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 2002; 5: 856-60.
12. Sui GP, Rothery S, Dupont E, Fry CH, Severs NJ. Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int 2002; 90: 118-29.
13. Sui GP, Wu C, Fry CH. Electrical characteristics of suburothelial cells isolated from the human bladder. J.Urol 2004; 171 (2 Pt 1): 938-43.
14. McCloskey KD, Gurney AM. Kit positive cells in the guinea pig bladder. J.Urol 2002; 168: 832-6.
15. Hashitani H, Yanai Y, Suzuki H. Role of interstitial cells and gap junctions in the transmission of spontaneous Ca2+ signals in detrusor smooth muscles of the guinea-pig urinary bladder. J.Physiol 2004; 559 (Pt 2): 567-81.
16. Burnstock G. Purinergic signalling in lower urinary tract. In: Abbracchio MP, Williams M, eds. Handbook of Experimental Pharmacology, Vol 151/I Purinergic and Pyrimidinergic Signalling I Molecular, Nervous and Urogenitary System Function. Berlin Heidelberg: Springer Verlag, 2001: 423-515.
17. Pandita RK, Andersson KE. Intravesical adenosine triphosphate stimulates the micturition reflex in awake, freely moving rats. J.Urol 2002; 168: 1230-4.
18. Cockayne DA, Hamilton SG, Zhu QM et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 2000; 407: 1011-5.
19. Vlaskovska M, Kasakov L, Rong W et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J.Neurosci 2001; 21: 5670-7.
20. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J.Urol 2005; 174: 977-82.
21. Chess-Williams RG, Manandar A, Scott RL, Chapple CR. Which muscarinic receptor subtype predominates in the urothelium ? Fund Clin Pharmacol 2004: 18 (Suppl. 1): 32. (abstract P03.15).
22. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 2005; 65: 238-42.
23. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J.Urol 2005; 174: 2032-6.
24. Levin RM, Longhurst PA, Monson FC, Kato K, Wein AJ. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate Suppl 1990; 3: 9-26.
25. Levin RM, Levin SS, Zhao Y, Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur Urol 1997; 32 (Suppl. 1): 15-21.
26. Gosling JA, Kung LS, Dixon JS, Horan P, Whitbeck C, Levin RM. Correlation between the structure and function of the rabbit urinary bladder following partial outlet obstruction. J.Urol 2000; 163: 1349-56.
27. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004; 84: 935-86.
28. Turner WH, Brading AF. Smooth muscle of the bladder in the normal and the diseased state: Pathophysiology, diagnosis and treatment. Pharmacol Ther 1997; 75: 77-110.
29. Charlton RG, Morley AR, Chambers P, Gillespie JI. Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int 1999; 84: 953-60.
30. Mills IW, Greenland JE, McMurray G et al. Studies of the pathophysiology of idiopathic detrusor instability: The physiological properties of the detrusor smooth muscle and its pattern of innervation. J.Urol 2000; 163: 646-51.
31. Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001; 358: 401-3.
32. Andersson K-E, Yoshida M. Antimuscarinics and the overactive detrusor -which is the main mechanism of action ? Eur Urol 2003; 43: 1.
33. Christ GJ, Day NS, Day M et al. Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1241-8.
34. Wang HZ, Lee SW, Day NS, Christ GJ. Gap junction channel activity in cultured human bladder smooth muscle cell pairs: Gating and unitary conductances. Urology 2001; 57 (6 Suppl. 1): 111.
35. Neuhaus J, Weimann A, Stolzenburg JU, Wolburg H, Horn LC, Dorschner W. Smooth muscle cells from human urinary bladder express connexin 43 in vivo and in vitro. World J Urol 2002; 20: 250-4.
36. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J.Urol 1993; 150 (5 Pt 2): 1668-80.
37. Haefliger JA, Tissieres P, Tawadros T et al. Connexins 43 and 26 are differentially increased after rat bladder outlet obstruction. Exp Cell Res 2002; 274: 216-25.
38. Coolsaet BL, Van Duyl WA, Van Os-Bossagh P et al. New concepts in relation to urge and detrusor activity. Neurourol Urodyn 1993; 12: 463-71.
39. Schroder A, Uvelius B, Capello SA, Longhurst PA. Regional differences in bladder enlargement and in vitro contractility after outlet obstruction in the rabbit. J.Urol 2002; 168: 1240-6.
40. Brading AF. A myogenic basis for the overactive bladder. Urology 1997; 50 (6A Suppl.): 57-67.
41. Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308.
42. Michel MC, Vrydag W. alpha(1)-, alpha(2)- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147 (Suppl. 2): S88-S119.
43. Malloy BJ, Price DT, Price RR et al. Alpha1-adrenergic receptor subtypes in human detrusor. J.Urol 1998; 160 (3 Pt 1): 937-43.
44. Perlberg S, Caine M. Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability. Urology 1982; 20: 524-7.
45. Sundin T, Dahlstrom A. The sympathetic innervation of the urinary bladder and urethra in the normal state and after parasympathetic denervation at the spinal root level. An experimental study in cats. Scand J Urol Nephrol 1973; 7: 131-49.
46. Hampel C, Dolber PC, Smith MP et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J.Urol 2002; 167: 1513-21.
47. Gu BJ, Ishizuka O, Igawa Y, Nishizawa O, Andersson KE. Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction. J.Urol 2002; 167: 1887-91.
48. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J.Urol 2003; 170 (2 Pt 1): 649-53.
49. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J.Urol 2003; 169: 2253-6.
50. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20.
51. Lee KS, Choo MS, Kim DY et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: A prospective, randomized, controlled multicenter study. J.Urol 2005; 174 (4 Pt 1): 1334-8.
52. Athanasopoulos A, Perimenis P. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Expert Opin Pharmacother 2005; 6: 2429-33.
53. Ruggieri Sr MR, Braverman AS, Pontari MA. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J.Urol 2005; 174: 1743-8.
54. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. Eur Urol 2006; 49 (4): 651-9.
55. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review. BMJ 2003; 326: 841-4.
56. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999; 64: 419-28.
57. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J.Auton Pharmacol 2001; 21: 243-8.
58. Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002; 136: 641-3.
59. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J.Pharmacol Exp Ther 2004; 309: 1148.
60. Kories C, Czyborra C, Fetscher C, Schneider T, Krege S, Michel MC. Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: Differential regulation of M2 and M3 receptors ? Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 524-31.
61. Hegde SS, Choppin A, Bonhaus D et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997; 120: 1409-18.
62. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R. The role of M2 muscarinic receptor subtypes mediating contraction of the circular and longitudinal smooth muscle of the pig proximal urethra. J.Urol 2002; 168: 308-14.
63. Matsui M, Motomura D, Karasawa H et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 2000; 97: 9579-84.
64. Igawa Y, Zhang X, Nishizawa O et al. Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J.Urol 2004; 172 (6, Part 1 of 2): 2460-4.
65. Somogyi GT, de Groat WC. Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J.Auton Nerv Syst 1992; 37: 89.
66. Tobin G, Sjögren C. Prejunctional facilitatory and inhibitory modulation of parasympathetic nerve transmission in the rabbit urinary bladder. J.Autonom Nerv Syst 1998; 68: 153.
67. Inadome A, Yoshida M, Takahashi W et al. Prejunctional muscarinic receptors modulating acetylcholine release in rabbit detrusor smooth muscles. Urol Int 1998; 61: 135.
68. D'Agostino G, Bolognesi ML, Lucchelli A et al. Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: Involvement of the M4 receptor subtype. Br J Pharmacol 2000; 129: 493.
69. Somogyi GT, de Groat WC. Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci 1999; 64: 411.
70. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005; 144: 1089-99.
71. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004; 63 (3 Suppl. 1): 17-23.
72. de Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In: CA Maggi, ed. The Autonomic Nervous System. Vol. 6, Chapter 8, Nervous Control of the Urogenital System. London, UK: Harwood Academic Publishers, 1993: 227-89.
73. Schurch B, de Seze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomised, placebo-controlled 6-month study. J.Urol 2005: 174: 196-200.
74. Schulte-Baukloh H, Weiss C, Stolze T et al. Botulinum-A toxin detrusor and sphincter injection in treatment of OAB syndrome: Objective outcome and patient satisfaction. Eur Urol 2005: 48: 984-90.
75. Sjögren C, Andersson K-E, Husted S, Mattiasson A, Møller-Madsen B. Atropine resistance of the transmurally stimulated isolated human bladder. J.Urol 1982; 128: 1368-71.
76. Husted S, Sjogren C, Andersson KE. Direct effects of adenosine and adenine nucleotides on isolated human urinary bladder and their influence on electrically induced contractions. J.Urol 1983; 130: 392-8.
77. Sibley GN. A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J.Physiol 1984; 354: 431-43.
78. Smith DJ, Chapple CR. In vitro response of human bladder smooth muscle in unstable obstructed male bladders: A study of pathophysiological causes ? Neurourol Urodyn 1994; 134: 14-5.
79. Bayliss M, Wu C, Newgreen D, Mundy AR, Fry CH. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J.Urol 1999; 162: 1833-9.
80. O'Reilly BA, Kosaka AH, Knight GF et al. P2X receptors and their role in female idiopathic detrusor instability. J.Urol 2002; 167: 157-64.
81. Palea S, Artibani W, Ostardo E, Trist DG, Pietra C. Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis. J.Urol 1993; 150: 2007-12.
82. Wammack R, Weihe E, Dienes H-P, Hohenfellner R. Die neurogene blase in vitro. Akt Urol 1995; 26: 16-8.
83. Yoshida M, Homma Y, Inadome A et al. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol 2001; 36: 99-109.
84. Lee HY, Bardini M, Burnstock G. Distribution of P2X receptors in the urinary bladder and the ureter of the rat. J.Urol 2000; 163: 2002-7.
85. O'Reilly BA, Kosaka AH, Chang TK et al. A quantitative analysis of purinoceptor expression in human fetal and adult bladders. J.Urol 2001; 165: 1730-4.
86. Moore KH, Ray FR, Barden JA. Loss of purinergic P2X(3) and P2X(5) receptor innervation in human detrusor from adults with urge incontinence. J.Neurosci 2001; 21: RC166.
87. Harvey RA, Skennerton DE, Newgreen D, Fry CH. The contractile potency of adenosine triphosphate and ecto-adenosine triphosphatase activity in guinea pig detrusor and detrusor from patients with a stable, unstable or obstructed bladder. J.Urol 2002; 168: 1235-9.
88. O'Reilly BA, Kosaka AH, Chang TK, Ford AP, Popert R, McMahon SB. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int 2001; 87: 617-22.
89. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human DO. J.Urol 2005: 174: 977-82.
90. Andersson KE. Treatment of the overactive bladder: Possible central nervous system drug targets. Urology 2002; 59 (5 Suppl. 1): 18-24.
91. Ishizuka O, Persson K, Mattiasson A, Naylor A, Wyllie M, Andersson K. Micturition in conscious rats with and without bladder outlet obstruction: Role of spinal alpha 1-adrenoceptors. Br J Pharmacol 1996; 117: 962-6.
92. Gu BJ, Ishizuka O, Igawa Y, Nishizawa O, Andersson KE. Role of supraspinal tachykinins for micturition in conscious rats with and without bladder outlet obstruction. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 543-8.
93. Steers WD, Ciambotti J, Etzel B, Erdman S, de Groat WC. Alterations in afferent pathways from the urinary bladder of the rat in response to partial urethral obstruction. J.Comp Neurol 1991; 310: 401-10.
94. Chai TC, Gemalmaz H, Andersson KE, Tuttle JB, Steers WD. Persistently increased voiding frequency despite relief of bladder outlet obstruction. J.Urol 1999; 161: 1689-93.
95. Downie JW. Pharmacological manipulation of central micturition circuitry. Curr Opin CPNS Invest Drugs 1999; 1: 231-9.
96. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001; 41: 691-721.
97. Andersson K-E. New pharmacologic targets for the treatment of the overactive bladder: An update. Urology 2004; 63 (3 Suppl. 1): 32-41.
98. Carbone A, Tubaro A, Morello P et al. The effect of gabapentin on neurogenic detrusor overactivity, a pilot study. Eur Urol 2003; Suppl. 2: 141. (Abstract 555).
99. Kim YT, Kwon DD, Kim J, Kim DK, Lee JY, Chancellor MB. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol 2004; 30: 275-8.
100. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J.Biol Chem 1996; 271: 5768-76.
101. Holstege G. Micturition and the soul. J.Comp Neurol 2005; 493: 15-20.